Optiscan ASX Announcement Company Update Highlights:
- Optiscan expects additional cash receipts including from Carl Zeiss Meditec for in excess of $200k.
- Total cash receipts from end of February till end of April are expected to exceed $900k.
- Leading medical journal, Nature Biomedical Engineering, publishes study led by Memorial Sloan Kettering Cancer Centre researchers confirming the potential for Optiscan technology to be used for “…intraoperative, PARPi-FL-based in vivo imaging without tissue excision.”
To read the full announcement, click here.
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.